SEARCH

SEARCH BY CITATION

References

  • 1
    Hauschild A, Weichenthal M, Balda BR, Becker JC, Wolff HH, Tilgen W, Schulte KW, Ring J, Schadendorf D, Lischner S, Burg G, Dummer R. Prospective randomized trial of interferon α-2b and interleukin-2 as adjuvant treatment for resected intermediate- and high-risk primary melanoma without clinically detectable node metastasis. J Clin Oncol 2003; 21: 288388.
  • 2
    Hancock BW, Wheatley K, Harris S, Ives N, Harrison G, Horsman JM, Middleton MR, Thatcher N, Lorigan PC, Marsden JR, Burrows L, Gore M. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study–United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon α-2a in high-risk resected malignant melanoma. J Clin Oncol 2004; 22: 5361.
  • 3
    Kleeberg UR, Suciu S, Brocker EB, Ruiter DJ, Chartier C, Lienard D, Marsden J, Schadendorf D, Eggermont AM; EORTC Melanoma Group in cooperation with the German Cancer Society (DKG). Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-α2b versus rIFN-γ versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness > 3 mm) or regional lymph node metastasis. Eur J Cancer 2004; 40: 390402.
  • 4
    Panagopoulos E, Murray D. Metastatic malignant melanoma of unknown primary origin: a study of 30 cases. J Surg Oncol 1983; 23: 810.
  • 5
    Barnetson RS, Halliday GM. Regression in skin tumours: a common phenomenon. Australas J Dermatol 1997; 38: S63S65.
  • 6
    Menzies SW, McCarthy WH. Complete regression of primary cutaneous malignant melanoma. Arch Surg 1997; 132: 5536.
  • 7
    Wagner SN, Schultewolter T, Wagner C, Briedigkeit L, Becker JC, Kwasnicka HM, Goos M. Immune response against human primary malignant melanoma: a distinct cytokine mRNA profile associated with spontaneous regression. Lab Invest 1998; 78: 54150.
  • 8
    Dissemond J, Gotte P, Mors J, Lindeke A, Goos M, Ferrone S, Wagner SN. Association of TAP1 downregulation in human primary melanoma lesions with lack of spontaneous regression. Melanoma Res 2003; 13: 2538.
  • 9
    van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254: 16437.
  • 10
    Smith C, Cerundolo V. Immunotherapy of melanoma. Immunology 2001; 104: 17.
  • 11
    Khong HT, Wang QJ, Rosenberg SA. Identification of multiple antigens recognized by tumor-infiltrating lymphocytes from a single patient: tumor escape by antigen loss and loss of MHC expression. J Immunother 2004; 27: 18490.
  • 12
    Vicari AP, Caux C, Trinchieri G. Tumour escape from immune surveillance through dendritic cell inactivation. Semin Cancer Biol 2002; 12: 3342.
  • 13
    Whiteside TL. Tumor-induced death of immune cells: its mechanisms and consequences. Semin Cancer Biol 2002; 12: 4350.
  • 14
    Ruiz-Cabello F, Cabrera T, Lopez-Nevot M, Garrido F. Impaired surface antigen presentation in tumors: implications for T cell-based immunotherapy. Semin Cancer Biol 2002; 12: 4035.
  • 15
    Seliger B, Cabrera T, Garrido F, Ferrone S. HLA class I antigen abnormalities and immune escape by malignant cells. Semin Cancer Biol 2002; 12: 313.
  • 16
    Kageshita T, Hirai S, Ono T, Hicklin DJ, Ferrone S. Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression. Am J Pathol 1999; 154: 74554.
  • 17
    Kamarashev J, Ferrone S, Seifert B, Boni R, Nestle FO, Burg G, Dummer R. TAP1 down-regulation in primary melanoma lesions: an independent marker of poor prognosis. Int J Cancer 2001; 95: 238.
  • 18
    Cresswell AC, Sisley K, Laws D, Parsons MA, Rennie IG, Murray AK. Reduced expression of TAP-1 and TAP-2 in posterior uveal melanoma is associated with progression to metastatic disease. Melanoma Res 2001; 11: 27581.
  • 19
    Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, Rubin SC, Coukos G. Intratumoral T cells, recurrence and survival in epithelial ovarian cancer. N Engl J Med 2003; 348: 20313.
  • 20
    Seliger B, Ritz U, Abele R, Bock M, Tampe R, Sutter G, Drexler I, Huber C, Ferrone S. Immune escape of melanoma: first evidence of structural alterations in two distinct components of the MHC class I antigen processing pathway. Cancer Res 2001; 61: 864750.
  • 21
    Seliger B, Wollscheid U, Momburg F, Blankenstein T, Huber C. Characterization of the major histocompatibility complex class I deficiencies in B16 melanoma cells. Cancer Res 2001; 61: 10959.
  • 22
    Alimonti J, Zhang QJ, Gabathuler R, Reid G, Chen SS, Jefferies WA. TAP expression provides a general method for improving the recognition of malignant cells in vivo. Nat Biotechnol 2000; 18: 51520.
  • 23
    Harris MR, Lybarger L, Yu YY, Myers NB, Hansen TH. Association of ERp57 with mouse MHC class I molecules is tapasin dependent and mimics that of calreticulin and not calnexin. J Immunol 2001; 166: 668692.
  • 24
    Layton MG, Franks LM. Heterogeneity in a spontaneous mouse lung carcinoma: selection and characterisation of stable metastatic variants. Br J Cancer 1984; 49: 41521.
  • 25
    Kallfelz M, Jung D, Hilmes C, Knuth A, Jaeger E, Huber C, Seliger B. Induction of immunogenicity of a human renal-cell carcinoma cell line by TAP1-gene transfer. Int J Cancer 1999; 81: 12533.
  • 26
    Singal DP, Ye M, Bienzle D. Transfection of TAP 1 gene restores HLA class I expression in human small-cell lung carcinoma. Int J Cancer 1998; 75: 1126.
  • 27
    Gabathuler R, Reid G, Kolaitis G, Driscoll J, Jefferies WA. Comparison of cell lines deficient in antigen presentation reveals a functional role for TAP-1 alone in antigen processing. J Exp Med 1994; 180: 141525.
  • 28
    Lopez-Albaitero A, Nayak JV, Ogino T, Machandia A, Gooding W, DeLeo AB, Ferrone S, Ferris RL. Role of antigen-processing machinery in the in vitro resistance of squamous cell carcinoma of the head and neck cells to recognition by CTL. J Immunol 2006; 176: 34029.
  • 29
    White CA, Thomson SA, Cooper L, van Endert PM, Tampe R, Coupar B, Qiu L, Parsons PG, Moss DJ, Khanna R. Constitutive transduction of peptide transporter and HLA genes restores antigen processing function and cytotoxic T cell-mediated immune recognition of human melanoma cells. Int J Cancer 1998; 75: 5905.
  • 30
    Leitch J, Fraser K, Lane C, Putzu K, Adema GJ, Zhang QJ, Jefferies WA, Bramson JL, Wan Y. CTL-dependent and -independent antitumor immunity is determined by the tumor not the vaccine. J Immunol 2004; 172: 52005.
  • 31
    Jacobs BL, Langland JO. When two strands are better than one: the mediators and modulators of the cellular responses to double-stranded RNA. Virology 1996; 219: 33949.
  • 32
    Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3. Nature 2001; 413: 7328.
  • 33
    Seo N, Hayakawa S, Takigawa M, Tokura Y. Interleukin-10 expressed at early tumour sites induces subsequent generation of CD4(+) T-regulatory cells and systemic collapse of antitumour immunity. Immunology 2001; 103: 44957.